Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, that has met its primary endpoint in several Phase 2 and 3 clinical trials in China for the treatment of colorectal, lung and gastric cancers.Read More
BioLight Life Sciences (TASE:BOLT) and other shareholders of its subsidiary, IOPtima, entered into a binding agreement for the investment and acquisition in stages of IOPtima by Chengdu Kanghong Pharmaceutical Group of China.Read More
Maxim Group raised its price target for BeiGene (NASDAQ:BGNE) to $120 from $77 after the company announced preliminary data from its ongoing Phase 1/2 study of BGB-A317 (PD-1 antibody) in Chinese patients with advanced solid tumors at the 20th annual meeting of the Chinese Society of Clinical Oncology in Xiamen, China.Read More
American CryoStem (OTC:CRYO) has expanded its relationship with Health Innovative Technology (HIT) of Hong Kong.Read More
Microbix Biosystems (TSX:MBX) has signed a distribution agreement with Meridian Life Science, a wholly owned unit of Meridian Bioscience (NASDAQ:VIVO), a fully integrated global diagnostic and life sciences company.Read More
Vital Therapies (NASDAQ:VTL) updated its Phase 3 trial, VTL-308, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis.Read More
Avivagen (TSX-V:VIV) has signed an agreement with Shaanxi Jintai Mining, a widely diversified Chinese company, to form a joint venture company to commercialize OxC-beta Livestock in China.
The JV will initially target OxC-beta for use in poultry and swine, with an option for use in cattle and goats (bovines and caprines).Read More
Closely-held Mati Therapeutics has been granted a U.S. patent covering a method of providing a sustained drug release to an eye using a proprietary punctal plug design placed in the punctum (tear duct) over a treatment period.
The patent, which expires in 2028, complements earlier issued U.S. patent claims directed to the proprietary punctal plug for non-invasive sustained delivery of topical drugs to the eye. The proprietary technology is used for multiple disease states with consistent, sustained efficacy.Read More
Oramed Pharmaceuticals (NASDAQ:ORMP) has received a milestone payment of $4-million from Hefei Tianhui Incubator of Technologies (HTIT) of China.
The milestone is part of a license and investment agreement between Oramed and HTIT, and follows Oramed’s report of additional positive efficacy and safety data from a recently completed Phase 2b trial of its oral insulin product, ORMD-0801.Read More
Maxim Group cut its price target for “buy-rated” Celsion (NYSE:CLSN) to $4 from $9. The stock was quoted at $1.22 Friday afternoon.
“While we are believers in Celsion’s ThermoDox product and platform, we recognize that pivotal Phase 3 data [from the OPTIMA study] will not arrive until late 2018,” writes analyst Jason McCarthy.Read More
Oramed Pharmaceuticals (NASDAQ:ORMP) has received an official notification of granting patent right for the company’s patent for its invention titled, “Methods and Compositions for Oral Administrations of Proteins” by the State Intellectual Property Office of the People’s Republic of China.
The patent addresses Oramed’s platform technology, which underlies its products, including ORMD-0801, an orally ingestible insulin capsule.Read More
Avivagen (TSX-V:VIV) plans to collaborate with the Jintai group of companies for a joint venture to commercialize OxC-beta Livestock in China.
The companies plan to create a Sino-Canadian joint venture company based in Xi’an, Shaanxi province, to register and commercialize OxC-beta Livestock, initially for use in poultry and swine.Read More
Avivagen (TSX-V:VIV) has reported positive results of a trial of OxC-beta Livestock as a feed additive for swine run by COFCO Nutrition and Health Research Institute (COFCO NHRI) of Beijing.
The trial evaluated OxC-beta’s effect on growth efficiency and health of pigs raised under local conditions during the post-weaning “starter” period. OxC-beta enhanced growth in the “starter” pigs in this trial, a result consistent with previously-reported trials in swine and broiler poultry.Read More
In a letter to shareholders, Nadav Kidron, CEO of Oramed Pharmaceuticals (NASDAQ:ORMP), detailed the company’s recent achievements and future milestones.
“2015 was a very significant year for us at Oramed, setting the bar high for what we anticipate to be a momentous year ahead in 2016,” he added.Read More